| 期 |
栏目 |
标题 |
文件 |
| 卷 30, 编号 9/10 (2023) |
Cardiology |
The influence of genetic resistance to antiplatelet agents on clinical and laboratory parameters and outcomes in ST-segment elevation myocardial infarction |
|
| 卷 30, 编号 14 (2023) |
Cardiology |
Analysis of the structure of comorbidities and pharmacotherapy in patients with a combination of atrial fibrillation and coronary heart disease |
|
| 卷 31, 编号 1 (2024) |
Cardiology |
On the possible relationship between the presence of polymorphic variants of CYP3A4/5 cytochrome genes, their metabolic activity with rivaroxaban pharmacokinetics and the development of bleeding in patients with non-valvular atrial fibrillation and chronic kidney disease |
|
| 卷 31, 编号 4 (2024) |
Cardiology |
Pharmacotherapy of elderly multimorbid patients with atrial fibrillation in real clinical practice: practical application of STOPP/START criteria |
|
| 卷 31, 编号 6 (2024) |
Cardiology |
On the possible relationship between polymorphic variants of the CYP2C19 gene, residual concentration and the presence of bleeding in patients who have suffered acute coronary syndrome and are receiving clopidogrel as part of dual antithrombotic therapy |
|
| 卷 31, 编号 6 (2024) |
Pulmonology/ENT/ARVI |
Association between CES1, CYP3A genetic polymorphisms and remdesivir hepatotoxicity in patients with COVID-19 |
|
| 卷 31, 编号 9 (2024) |
Коморбидность |
Development of an algorithm for predicting the risk of cough development during enalapril therapy in patients with arterial hypertension |
|
